stemergie.com
About company
Stemergie is a spin-off company from the Geneva University Hospital (HUG) and the University of Geneva (UNIGE) and was incorporated in 2009. Stemergie develops treatments and diagnostics for cancers by targeting cancer-initiating cells (CIC), the roots of cancer. Stemergie's CIC based technology platform allows the identification, validation and development of treatments against brain CIC. With its proprietary methodology Stemergie is able to identify, isolate and enrich CIC independently of any marker. Stemergie plans to translate this technology to further types of CIC, in order to treat and diagnose melanoma as well as further oncology indications. Stemergie has identified and validated molecules that specifically eradicate brain CIC. These effective treatments targeting the roots of cancer in combination with the current standard treatments have a high potential to increase the survival rate of the brain tumor patient in the future.
